Company prepares marketing submission after treatment shows strong efficacy
Category: News
Decision introduces zolbetuximab for eligible patients in NHS Scotland
Dysport reduces muscle contractions by blocking the transmission of nerve impulses
Acquisition expands PMGroup’s commitment to transforming workplace health and organisational resilience
Regulator accepts supplemental application supported by positive phase 3 data
Investment to accelerate development of full‑format antibody capabilities on eProtein Discovery system
New manufacturing technologies aim to accelerate next-generation cell therapy development
Authorisation marks major step in European preparedness against ricin
Data shows potential route to overcoming resistance in aggressive colorectal tumours
Partnership will analyse m6A RNA modifications in patient samples to support development of STC‑15